| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1024510095 |
| P356 | DOI | 10.1038/179663A0 |
| P3181 | OpenCitations bibliographic resource ID | 2213308 |
| P698 | PubMed publication ID | 13418758 |
| P2093 | author name string | C HEIDELBERGER | |
| J SCHEINER | |||
| P DANNEBERG | |||
| R J SCHNITZER | |||
| N K CHAUDHURI | |||
| R DUSCHINSKY | |||
| D MOOREN | |||
| E PLEVEN | |||
| L GRIESBACH | |||
| P2860 | cites work | Chromatographic studies of nucleic acids; a technique for the identification and estimation of purine and pyrimidine bases, nucleosides and related substances | Q42626913 |
| Studies of nucleic acid synthesis in ascites tumor cells | Q74007787 | ||
| The fate of 6-mercaptopurine in mice | Q78573325 | ||
| The in vivo formation of citrate induced by fluoroacetate and its significance | Q80655039 | ||
| The Separation of Purine and Pyrimidine Bases and of Nucleotides by Ion Exchange | Q80929979 | ||
| P433 | issue | 4561 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 663-6 | |
| P577 | publication date | 1957-03-30 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Fluorinated pyrimidines, a new class of tumour-inhibitory compounds | |
| P478 | volume | 179 |
| Q33895644 | 18F-labeled radiopharmaceuticals for PET in oncology, excluding FDG. |
| Q53609164 | 2 phase mechanism of carcinogenesis |
| Q36046666 | 3-Ethyl-6-(4-fluoro-phen-yl)-7H-1,2,4-triazolo[3,4-b][1,3,4]thia-diazine |
| Q36045986 | 4-[(E)-(4-Fluoro-benzyl-idene)amino]-3-methyl-1H-1,2,4-triazole-5(4H)-thione |
| Q37405201 | 5-FLUOROURACIL AS A SELECTIVE AGENT FOR GROWTH OF LEPTOSPIRAE |
| Q54485345 | 5-Fluorouracil (FUra) |
| Q42272739 | 5-Fluorouracil and mucopeptide biosynthesis by Staphylococcus aureus |
| Q39418513 | 5-Fluorouracil chemotherapy upregulates cytokines and alters hippocampal dendritic complexity in aged mice. |
| Q34253978 | 5-Fluorouracil derivatives: a patent review. |
| Q27863350 | 5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity |
| Q41538707 | 5-Fluorouracil targets thymidylate synthase in the selective suppression of TH17 cell differentiation |
| Q33925505 | 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development |
| Q37334281 | 5-fu metabolism in cancer and orally-administrable 5-fu drugs. |
| Q40903149 | A Case of Hyperammonemia Associated with High Dihydropyrimidine Dehydrogenase Activity. |
| Q82226144 | A Facile and Stereocontrolled Synthesis of γ-Substituted γ-Fluoroglutamates by Conjugate Addition: Conflicting Effect between Fluorinated Enaminoester and Hinderered Michael Acceptor |
| Q36127088 | A REPORT OF THE SYSTEMIC USE OF 5-FLUOROURACIL IN THE TREATMENT OF CHINESE CANCER PATIENTS |
| Q41605727 | A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma |
| Q37889959 | A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma |
| Q35996020 | A meta-analysis of safety and efficacy on first-line S-1 therapy in cancer patients |
| Q46474564 | A note from history: Landmarks in history of cancer, Part 6. |
| Q38671965 | A novel antimetabolite: TAS-102 for metastatic colorectal cancer |
| Q45006319 | A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study |
| Q33998072 | A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer |
| Q36617702 | A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer |
| Q35567250 | A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage. |
| Q37999994 | A tale of two enzymes, deoxycytidylate deaminase and thymidylate synthase. |
| Q64992614 | A tannin compound from Sanguisorba officinalis blocks Wnt/β-catenin signaling pathway and induces apoptosis of colorectal cancer cells. |
| Q36236475 | A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing |
| Q36429575 | AN EARLY PHASE IN THE BACTERICIDAL ACTION OF 5-FLUOROURACIL ON E. COLI K(12). OSMOTIC IMBALANCE. |
| Q72689116 | Adjuvant chemotherapy of large bowel cancer |
| Q39813226 | Adjuvant treatment of colorectal cancer. Current status and concepts |
| Q71080696 | Advanced colorectal cancer treated with combined 5-fluorouracil and folinic acid: the experience within a surgical department |
| Q79425952 | Advances in the chemotherapy of solid tumors |
| Q53264472 | Advances in the preclinical testing of cancer therapeutic hypotheses. |
| Q38660825 | All-Atom MD Predicts Magnesium-Induced Hairpin in Chemically Perturbed RNA Analog of F10 Therapeutic. |
| Q51528554 | All-Atom Molecular Dynamics Reveals Mechanism of Zinc Complexation with Therapeutic F10. |
| Q62763957 | All-atom MD indicates ion-dependent behavior of therapeutic DNA polymer |
| Q38289914 | Alpha- and Beta-Cyclodextrin Inclusion Complexes with 5-Fluorouracil: Characterization and Cytotoxic Activity Evaluation. |
| Q35973180 | An FDA-Drug Library Screen for Compounds with Bioactivities against Meticillin-Resistant Staphylococcus aureus (MRSA) |
| Q63439685 | An in vitro model to study chemoresistance in non-Hodgkin's lymphoma patients over-expressing mutant p53 |
| Q44675584 | An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens |
| Q28482151 | Analysis of polymorphisms and haplotype structure of the human thymidylate synthase genetic region: a tool for pharmacogenetic studies |
| Q79429671 | Antagonists of purine and pyrimidine metabolites and of folic acid |
| Q58952806 | Anti-Tumour Activity of 5-Mercaptouracil |
| Q26801911 | Anti-angiogenic agents in metastatic colorectal cancer |
| Q36639291 | Anticancer drug discovery and pharmaceutical chemistry: a history |
| Q35826334 | Antimetabolite Treatment for Pancreatic Cancer |
| Q34850202 | Antimetabolite incorporation into DNA: structural and thermodynamic basis for anticancer activity |
| Q39339684 | Antineoplastic drugs and their analysis: a state of the art review |
| Q38503308 | Antivitamins for Medicinal Applications |
| Q71911633 | Assessment of the biodistribution and metabolism of 5-fluorouracil as monitored by 18F PET and 19F MRI: a comparative animal study |
| Q37137408 | Assessment of the evolution of cancer treatment therapies |
| Q39575536 | Attenuated mumps virus therapy of carcinoma of the maxillary sinus |
| Q37700995 | Automated modular synthesis of aptamer-drug conjugates for targeted drug delivery. |
| Q67318870 | Autoradiographic Distribution Studies of 2-14C-Fluorouracil following Oral or Intravenous Administration in Mice Bearing Solid Sarcoma-180 |
| Q34693332 | Barbiturate Interaction with Phosphatidylcholine |
| Q27863401 | Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil |
| Q38617495 | Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer |
| Q38200600 | Beyond Thymidylate Synthase and Dihydrofolate Reductase: Impact of Non-coding microRNAs in Anticancer Chemoresistance |
| Q92002034 | Beyond tissue concentrations: antifungal penetration at the site of infection |
| Q28336165 | Biochemical mechanisms for the scheduled synergism of (alpha S, 5S)-2 amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid and 5-fluorouracil in P388 leukemia |
| Q78128657 | Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study |
| Q37855365 | Biochemical modulation of fluoropyrimidines by antifolates and folates in an in vitro model of human leukemia |
| Q73133998 | Biochemical modulation of the catabolism and tissue uptake of the anticancer drug 5-fluorouracil by 5-bromovinyluracil: assessment with metabolic (19)F MR imaging |
| Q36705141 | Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators |
| Q39828742 | Biological and Biochemical Effects of Phenylalanine Analogs |
| Q40859206 | Biomodulation of Fluorouracil in colorectal cancer |
| Q69057151 | Blood and neoplastic diseases. A rational approach to the chemotherapy of human malignant disease. I |
| Q35052311 | Breast cancer in the 20 century: quest for the ideal therapy |
| Q77161351 | CHEMOTHERAPY OF MALIGNANCIES OF THE GASTROINTESTINAL TRACT |
| Q30371382 | CRL4Cdt2 E3 ubiquitin ligase and proliferating cell nuclear antigen (PCNA) cooperate to degrade thymine DNA glycosylase in S phase |
| Q64899590 | Cancer Cells Tune the Signaling Pathways to Empower de Novo Synthesis of Nucleotides. |
| Q47100567 | Cancer Metabolism: a Hope for Curing Cancer |
| Q37017121 | Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors |
| Q101573919 | Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy |
| Q71189973 | Cancer chemotherapy |
| Q33887986 | Cancer targeted therapeutics: From molecules to drug delivery vehicles. |
| Q33775256 | Candida infections and their prevention |
| Q73197720 | Capecitabine |
| Q33611917 | Cardiotoxicity of the antiproliferative compound fluorouracil |
| Q51529846 | Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. |
| Q89558416 | Cell division during the development ofArtemia salina |
| Q40596146 | Cellular resistance to cancer chemotherapy. |
| Q46865430 | Characterization of 5-fluorouracil microspheres for colonic delivery |
| Q47324426 | Charomers-Interleukin-6 Receptor Specific Aptamers for Cellular Internalization and Targeted Drug Delivery |
| Q40844614 | Chemotherapeutic drug resistance in the management of head and neck cancer |
| Q37010595 | Chemotherapy and immunotherapy of colorectal cancer |
| Q36788364 | Chemotherapy in Malignant Disease: The Present Position |
| Q68494816 | Chemotherapy of colon and rectal cancer |
| Q78986417 | Chemotherapy of solid tumors |
| Q39451638 | Chemotherapy studies in autochthonous rat tumors. Forestomach and bladder cancer |
| Q24648764 | Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma |
| Q44221353 | Chemotherapy, Immunotherapy and Chemoimmunotherapy of Colorectal Cancer |
| Q70137976 | Chronic infusion of 5-fluoro-2'-deoxyuridine (5-FUDR) into the hepatic artery of the dog |
| Q78934322 | Clinical applications of the fluorinated pyrimidines |
| Q41338694 | Clinical investigators as critical determinants in pharmaceutical innovation |
| Q34606481 | Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics |
| Q77376203 | Cobalamin-dependent methionine synthase and serine hydroxymethyltransferase: targets for chemotherapeutic intervention? |
| Q64229063 | Colorectal Cancer Biomarkers in the Era of Personalized Medicine |
| Q34769536 | Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts. |
| Q42439493 | Combined cytostatic and surgical treatment of extensive basal cell epitheliomata |
| Q69534735 | Commentary on 'The Toxicity of Fluoroacetate and the Tricarboxylic Acid Cycle' |
| Q37407705 | Comparative effects of 5-fluorouracil on strains of Bacillus megaterium |
| Q40853983 | Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer |
| Q34523575 | Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma |
| Q40608060 | Comparison of different methods to assess the cytotoxic effects of cytosine deaminase and thymidine kinase gene therapy |
| Q44016718 | Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial |
| Q36460679 | Comparison of the Actions of 5-Fluorouracil and Ftorafur in Escherichia coli |
| Q70056784 | Comparison of the pyrimidine nucleoside phosphorylase activity in human tumors and normal tissues |
| Q73206714 | Complete response of a gastric primary after a short but toxic course of 'S-1' EORTC Early Clinical Studies Group |
| Q37485627 | Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy |
| Q36079497 | Continuous 5-fluorouracil in the treatment of breast cancer |
| Q72758679 | Continuous Preoperative Intra-Arterial Perfusion of Renal Tumors with Cheiyiotherapeutic Agents |
| Q43048728 | Correlation between thymidylate synthase gene variants, RNA and protein levels in primary colorectal adenocarcinomas |
| Q34473056 | Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA. |
| Q45186541 | Crystal structure and conformation of 5-fluorouridine: conformational preferences for 5-fluorinated pyranosides |
| Q41864040 | Crystal structure and hydrogen-bonding patterns in 5-fluoro-cytosinium picrate |
| Q50959493 | Crystal structure of the active form of native human thymidylate synthase in the absence of bound substrates. |
| Q38254307 | DNA synthesis inhibitors for the treatment of gastrointestinal cancer |
| Q91741543 | DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report |
| Q48310481 | DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer. |
| Q39116691 | Design and synthesis of fluoroacylshikonin as an anticancer agent. |
| Q47933025 | Determination of N3-methyl-5'-deoxy-5-fluorouridine, a novel metabolite of doxifluridine, in body fluids by high performance liquid chromatography |
| Q70515527 | Determination of a novel 5-fluorouracil derivative in rat and human plasma by high-performance liquid chromatography |
| Q90724136 | Development of a Correlative Strategy To Discover Colorectal Tumor Tissue Derived Metabolite Biomarkers in Plasma Using Untargeted Metabolomics |
| Q36999930 | Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study |
| Q76485303 | Different effects of 5-fluorodeoxyuridine and 5-bromodeoxuridine on the frequencies of chromatid aberrations obtained in vicia faba after irradiation with X-rays |
| Q52584555 | Differential glucose requirement in skin homeostasis and injury identifies a therapeutic target for psoriasis. |
| Q54035916 | Differential growth inhibition by 5-fluorouracil in human colorectal carcinoma cell lines. |
| Q44003038 | Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients |
| Q30654112 | Discovery of an acyclic nucleoside phosphonate that inhibits Mycobacterium tuberculosis ThyX based on the binding mode of a 5-alkynyl substrate analogue |
| Q36398005 | Dissociation of macromolecular synthetic processes in T2-infected E. coli |
| Q40152131 | Distribution of 18F-5-Fluorouracil in tumor-bearing mice and rats |
| Q36080058 | Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study |
| Q92356396 | Doublecotin-Like Kinase 1 Increases Chemoresistance of Colorectal Cancer Cells through the Anti-Apoptosis Pathway |
| Q48317852 | Drug delivery of oral anti-cancer fluoropyrimidine agents |
| Q35336154 | Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections |
| Q52866005 | Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. |
| Q72621086 | Early post-operative 5-fluorouracil does not affect the healing of experimental intestinal anastomoses |
| Q53426526 | Effect of 5-fluorouracil on gastrointestinal carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats. |
| Q59004762 | Effect of Fluorinated Pyrimidines on Herpes Simplex Virus |
| Q72822110 | Effect of guanosine on antitumor activity of fluorinated pyrimidines against P 388 leukemia |
| Q58975737 | Effect of some Metabolic Inhibitors on Antibody Formation |
| Q44215940 | Effect of ultraviolet light on tobacco mosaic virus containing 5-fluorouracil |
| Q36425270 | Effects of 5-fluorodeoxyuridine and related halogenated pyrimidines on the sand-dollar embryo. |
| Q59006657 | Effects of Certain Anti-Tumour Chemicals on a Tumorous Nicotiana Hybrid |
| Q54401980 | Effects of Topically Applied 5-Fluorouracil in the Syrian Hamster |
| Q47721432 | Effects of actinomycin D and 5-fluorouracil on the formation of enzymes in Bacillus subtilis |
| Q40632150 | Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implications |
| Q37429373 | Effects of uracil and thymidine on the development of resistance to 5-fluorouracil in Pediococcus cerevisiae |
| Q34429445 | Efficacy of S-1 in colorectal cancer |
| Q38895189 | Electrostatic potentials and average electron densities of bioisosteres in methylsquarate and acetic acid |
| Q88549071 | Emerging Systemic Therapies for Colorectal Cancer |
| Q26774720 | Emerging role of S-1 in gastric cancer |
| Q44961602 | Enantioselective organocatalytic fluorination-induced Wagner-Meerwein rearrangement |
| Q46417127 | Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters |
| Q70518728 | Enhanced response of leukemic (L1210) mice to combination chemotherapy with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388) and 5-fluorouracil (NSC-19893) |
| Q33566824 | Enhancement of TRAIL-induced apoptosis by 5-fluorouracil requires activating Bax and p53 pathways in TRAIL-resistant lung cancers |
| Q46941049 | Enzymatic activities of uridine and thymidine phosphorylase in normal and cancerous uterine cervical tissues |
| Q24642847 | Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer |
| Q34847802 | Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? |
| Q41842495 | Evaluation of intralesional 5% 5-fluorouracil in resistant localized plaque psoriasis |
| Q37298361 | Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer |
| Q59329233 | Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium |
| Q37901557 | Evolution of systemic therapy for metastatic colorectal cancer |
| Q92029975 | Exosomal transfer of p-STAT3 promotes acquired 5-FU resistance in colorectal cancer cells |
| Q45204501 | Experimental and clinical studies on nucleoside analogs as antitumor agents |
| Q64069603 | Exploiting Prophage-Mediated Lysis for Biotherapeutic Release by |
| Q38466329 | Exploiting replicative stress to treat cancer |
| Q43502786 | Expression of human mitochondrial thymidine kinase in Escherichia coli: correlation between the enzymatic activity of pyrimidine nucleoside analogues and their inhibitory effect on bacterial growth |
| Q39883539 | Expression profiling of nucleotide metabolism-related genes in human breast cancer cells after treatment with 5-fluorouracil |
| Q52743840 | Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer. |
| Q76606253 | FLUORINATED PYRIMIDINES. XIX. SOME BIOLOGICAL EFFECTS OF 5-TRIFLUOROMETHYLURACIL AND 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE ON ESCHERICHIA COLI AND BACTERIOPHAGE T4B |
| Q50090153 | Fabrication and Use of Poly(d,l-lactide-co-glycolide)-Based Formulations Designed for Modified Release of 5-Fluorouracil |
| Q35629061 | First-line treatment strategies to improve survival in patients with advanced colorectal cancer |
| Q71926478 | Fluor-derivatives of biogenic aliphatic amino acids |
| Q36974059 | Fluorinated Nucleosides: Synthesis and Biological Implication |
| Q35829825 | Fluorinated tracers for imaging cancer with positron emission tomography |
| Q38933998 | Fluorination methods for drug discovery and development |
| Q34635770 | Fluorine (19F) MRS and MRI in biomedicine |
| Q34172495 | Fluorine in medicinal chemistry: a century of progress and a 60-year retrospective of selected highlights |
| Q42099161 | Fluorine-rich planetary environments as possible habitats for life |
| Q38817372 | Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management. |
| Q32052960 | Fluorouracil and the new oral fluorinated pyrimidines |
| Q39920504 | From wild fowl to stalking horses: Alchemy in chemotherapy.Fifth annual David A. Karnofsky memorial lecture |
| Q35011904 | Future potential of thymidylate synthase inhibitors in cancer therapy |
| Q55014747 | Gene dosage effects in yeast support broader roles for the LOG1, HAM1 and DUT1 genes in detoxification of nucleotide analogues. |
| Q42057665 | Gene expression and effects of orally active derivatives of fluoropyrimidine on gastric and colorectal cancer |
| Q28547966 | Gypenosides Synergistically Enhances the Anti-Tumor Effect of 5-Fluorouracil on Colorectal Cancer In Vitro and In Vivo: A Role for Oxidative Stress-Mediated DNA Damage and p53 Activation |
| Q89542508 | HJC0152 suppresses human non-small-cell lung cancer by inhibiting STAT3 and modulating metabolism |
| Q52668182 | HMGA2 enhances 5-fluorouracil chemoresistance in colorectal cancer via the Dvl2/Wnt pathway. |
| Q35226944 | Herb-drug pharmacokinetic interaction of a traditional chinese medicine jia-wei-xiao-yao-san with 5-Fluorouracil in the blood and brain of rat using microdialysis |
| Q43777035 | High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro |
| Q67318396 | High-performance liquid chromatographic analysis of 5-fluorouracil in plasma |
| Q28821950 | High-throughput imaging-based nephrotoxicity prediction for xenobiotics with diverse chemical structures |
| Q67901378 | Highly sensitive method for the determination of 5-fluorouracil in biological samples in the presence of 2'-deoxy-5-fluorouridine by gas chromatography—mass spectrometry |
| Q51066803 | Human uridine phosphorylase-1 inhibitors: a new approach to ameliorate 5-fluorouracil-induced intestinal mucositis. |
| Q90226833 | Hyperglycemia Associated Metabolic and Molecular Alterations in Cancer Risk, Progression, Treatment, and Mortality |
| Q37258328 | Hypermutation of DPYD Deregulates Pyrimidine Metabolism and Promotes Malignant Progression. |
| Q43207131 | Identifying new targets for cancer drug 5'-fluorouracil |
| Q36398732 | Identifying therapeutic targets in gastric cancer: the current status and future direction |
| Q51785962 | Implantable enzyme capsules for cancer chemotherapy from bakers' yeast cytosine deaminase immobilized on epoxy-acrylic resin and urethane prepolymer. |
| Q46707141 | Improvement in 5-fluorouracil (5-FU) and 5-fluoro-2'-deoxyuridine (FdUrd) concentration by 5-fluorouracil-polyethylene-glycol-liposomes in abdominal stop-flow: treatment of VX2 liver-tumor-bearing rabbits |
| Q36403769 | Improving the anti-tumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation |
| Q41028056 | In Vitro Studies of 5-Fluorocytosine Resistance in Candida albicans and Torulopsis glabrata |
| Q62500521 | In vitro toxicity of N3-methyl-5′-deoxy-5-fluorouridine, a novel metabolite of doxifluridine: a bioanalytical investigation |
| Q35646810 | Incorporation of 5-fluorouracil into U2 snRNA blocks pseudouridylation and pre-mRNA splicing in vivo |
| Q45209289 | Incorporation of 5-fluorouracil into the transfer RNA of Escherichia coli K12W6 and its effect on the methylation of uracil |
| Q92514286 | Induced miR-31 by 5-fluorouracil exposure contributes to the resistance in colorectal tumors |
| Q60088163 | Induction by 5-Fluorouracil of Bacteriophage Development in Lysogenic E. coil K12 (λ) |
| Q36216994 | Influence of 5-fluorouracil on ferredoxin reductase mRNA splice variants in colorectal carcinomas |
| Q42858753 | Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells |
| Q83238742 | Inhibition of Photoperiodic Induction by 5-Fluorouracil |
| Q41140314 | Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717. |
| Q44187667 | Interferon potentiates cytotoxic effects of 5-fluorouracil on cell proliferation of established human cell lines originating from neoplastic tissues |
| Q36136350 | Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer |
| Q43740909 | Intrathecal 5-fluorouracil in the rhesus monkey |
| Q36952188 | Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy |
| Q34210342 | LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients |
| Q72186031 | Labelling of ribosomal RNA peaks in the liver of rats after administration of tritiated fluorouracil |
| Q73549119 | Lack of carcinogenicity and increased survival in F344 rats treated with 5-fluorouracil for two years |
| Q40729120 | Limitations of the Use of 5-Fluorouracil as a Selective Agent for the Isolation of Leptospirae |
| Q39893194 | Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence |
| Q34110004 | Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials |
| Q46765481 | Looking for the right drug for the right patient: a tale of old drugs and new pathways |
| Q39465282 | Low-dose 5-fluorouracil in combination with salicylic acid for the treatment of actinic keratoses on the hands and/or forearms - results of a non-interventional study |
| Q35443005 | MECHANISMS OF RESISTANCE TO ANTICANCER AGENTS. |
| Q35184172 | Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids |
| Q78990800 | Management of Reticuloendothelial Malignancies |
| Q44187978 | Mass spectrometric study of some 4-pyrimidine carboxylic acids |
| Q59071437 | Massive Incorporation of 5-Fluorouracil into a Bacterial Ribonucleic Acid |
| Q52170109 | Mechanisms of Action and Modulation of Fluorouracil. |
| Q37804875 | Mechanisms of action of topical 5-fluorouracil: Review and implications for the treatment of dermatological disorders |
| Q78805183 | Mechanisms of drug action in leukemia |
| Q44512449 | Mechanisms of pharmacologic intervention in the vital functions of the cell |
| Q34322782 | Medical management of cutaneous malignancies |
| Q36639785 | Metabolism and mechanism of action of 5-fluorouracil |
| Q34547269 | Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs |
| Q36893806 | Metastatic colorectal cancer-past, progress and future |
| Q33359886 | Methoxylation enhances stilbene bioactivity in Caenorhabditis elegans |
| Q41902084 | MicroRNA-330 inhibited cell proliferation and enhanced chemosensitivity to 5-fluorouracil in colorectal cancer by directly targeting thymidylate synthase |
| Q36022236 | MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer |
| Q38768751 | MicroRNA-874 inhibits growth, induces apoptosis and reverses chemoresistance in colorectal cancer by targeting X-linked inhibitor of apoptosis protein |
| Q39016759 | MicroRNAs are important regulators of drug resistance in colorectal cancer |
| Q92541923 | MicroRNAs in Tumor Cell Metabolism: Roles and Therapeutic Opportunities |
| Q49564034 | Molecular Biology: Are We Getting Any Closer to Providing Clinically Useful Information? |
| Q67760095 | Multiple confirmatory trials. How can additional studies be of value? |
| Q50278227 | Mutation as an error in base pairing. I. The mutagenicity of base analogues and their incorporation into the DNA of Salmonella typhimurium |
| Q44472797 | Nanoceria-triggered synergetic drug release based on CeO(2) -capped mesoporous silica host-guest interactions and switchable enzymatic activity and cellular effects of CeO(2). |
| Q35875393 | New drugs for colorectal cancer. |
| Q42705196 | Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. |
| Q77397502 | Noninvasive determination of the arterial input function of an anticancer drug from dynamic PET scans using the population approach |
| Q71997774 | Novel lowly immunosuppressive antitumor fluorouridine derivative, UK-21: antitumor activity and effect on humoral immune response in mice |
| Q39940022 | Novel opportunities for thymidylate metabolism as a therapeutic target. |
| Q38794338 | Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications |
| Q64902008 | Nucleoside Analogues as Antibacterial Agents. |
| Q92935725 | O-Regioselective Synthesis with the Silver Salt Method |
| Q40004609 | On the nature of thymineless death |
| Q42321596 | Oncogenic regulation of tumor metabolic reprogramming |
| Q77809146 | Oral fluoropyrimidines in the treatment of colorectal cancer |
| Q34390375 | Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil? |
| Q38846339 | Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles. |
| Q92617945 | Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice |
| Q38603038 | P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting. |
| Q72680305 | Palliative and adjunctive measures in rectal cancer |
| Q37114275 | Participation of DNA repair in the response to 5-fluorouracil |
| Q48322740 | Paul Ehrlich's magic bullet concept: 100 years of progress |
| Q55107856 | Perioperative chemotherapy with pemetrexed and cisplatin for pulmonary large-cell neuroendocrine carcinoma: a case report and literature review. |
| Q44987455 | Peripheal blood toxicity of topical 5-fluorouracil on the Syrian hamster cheek pouch |
| Q38166233 | Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. |
| Q36326214 | Pharmacogenetics of colorectal cancer |
| Q34008793 | Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years |
| Q42691338 | Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update |
| Q35873676 | Pharmacogenomics and stomach cancer. |
| Q36441493 | Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy |
| Q37728873 | Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients |
| Q33581242 | Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel |
| Q55040229 | Pharmacokinetics of continuous transarterial infusion of 5-fluorouracil in patients with advanced hepatocellular carcinoma. |
| Q26769850 | Pharmacologic resistance in colorectal cancer: a review |
| Q37500096 | Pharmacology and pharmacogenetics of chemotherapeutic agents |
| Q42793414 | Pharmacology of perioperative 5‐Fluorouracil |
| Q43280939 | Pharmacology, pharmacogenetics, and pharmacoepidemiology: three ps of individualized therapy |
| Q67993427 | Phase II study of gemcitabine in advanced colorectal adenocarcinoma |
| Q47268080 | Phosphoribosyl pyrophosphate, pool size and tissue levels as a determinant of 5-fluorouracil response in murine colonic adenocarcinomas |
| Q30426511 | Plant-derived anticancer agents |
| Q36420719 | Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology |
| Q59069547 | Possible Enzymic Mechanism for the Development of Resistance against Fluorouracil in Ascites Tumours |
| Q37406869 | Possible role of thymidine phosphorylase in gynecological tumors as an individualized treatment strategy |
| Q37311933 | Preclinical screening methods in cancer |
| Q44458788 | Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer |
| Q33320579 | Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy |
| Q68445322 | Preoperative irradiation and 5-fluorouracil suppository for carcinoma of the rectum |
| Q38232067 | Priming cancer cells for drug resistance: role of the fibroblast niche |
| Q34325743 | Programmed chemotherapy for patients with metastatic unresectable gastric cancer. |
| Q35039113 | Proteomic analysis of differentially expressed proteins in 5-fluorouracil-treated human breast cancer MCF-7 cells |
| Q34347434 | Protonation preferentially stabilizes minor tautomers of the halouracils: IRMPD action spectroscopy and theoretical studies. |
| Q26865050 | Pseudouridines in spliceosomal snRNAs |
| Q34019673 | Pyrimidine metabolism in man. V. The measurement in vivo of the biochemical effect of antineoplastic agents in animal and human subjects |
| Q76898304 | RADIOAUTOGRAPHIC STUDY OF THE EFFECTS OF 5-FLUORODEOXYURIDINE, ACTINOMYCIN AND PUROMYCIN IN ACETABULARIA MEDITERANEA |
| Q46446260 | Radiation dose estimates for [18F]5-fluorouracil derived from PET-based and tissue-based methods in rats |
| Q59081922 | Radiosensitization Of E. Coli by Purine and Pyrimidine Analogues Incorporated in Deoxyribonucleic Acid |
| Q35009893 | Raltitrexed: optimism and reality |
| Q38268619 | Recent studies of 5-fluorouracil resistance in pancreatic cancer |
| Q35556789 | Reexamining a proposal: thymidylate synthase 5'-untranslated region as a regulator of translation efficiency. |
| Q38211868 | Relationship between head and neck cancer therapy and some genetic endpoints |
| Q69934719 | Reminiscence and experience in experimental chemotherapy of cancer |
| Q40187481 | Repurposing of nucleoside- and nucleobase-derivative drugs as antibiotics and biofilm inhibitors. |
| Q26781245 | Research into cancer metabolomics: Towards a clinical metamorphosis |
| Q35567272 | Resistance to antifolates |
| Q41398588 | Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage |
| Q64997072 | Ribose-transfer Activity from Uridine to 5-Fluorouracil in Ehrlich Ascites Tumor Cells |
| Q47849564 | Routes to drug design via bioisosterism of carboxyl and sulfonamide groups. |
| Q37974935 | S-1 as a core anticancer fluoropyrimidine agent |
| Q27700205 | Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo |
| Q39312759 | Semisynthetic ursolic acid fluorolactone derivatives inhibit growth with induction of p21(waf1) and induce apoptosis with upregulation of NOXA and downregulation of c-FLIP in cancer cells |
| Q35969001 | Shizukaol D, a Dimeric Sesquiterpene Isolated from Chloranthus serratus, Represses the Growth of Human Liver Cancer Cells by Modulating Wnt Signalling Pathway |
| Q40138085 | Solid Tumor Models for the Assessment of Different Treatment Modalities: VI: Perturbations in the Kinetics of Tumor and Host Organ Cellular Regulation Demonstrated by Single and Combined Experimental Therapy |
| Q39961474 | Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosyltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer |
| Q27006500 | Splice isoforms as therapeutic targets for colorectal cancer |
| Q38204673 | Standing the test of time: targeting thymidylate biosynthesis in cancer therapy |
| Q27675656 | Structure, stability and function of 5-chlorouracil modified A:U and G:U base pairs |
| Q42254777 | Structure-activity relationship of 1-propargyl-5-halopyrimidin-2-ones. Metaphase arresting properties and competitive inhibition of colchicine binding to tubulin |
| Q42697416 | Structures of a DNA Polymerase Inserting Therapeutic Nucleotide Analogues |
| Q46206827 | Studies on the mechanism of fluoropyrimidine cytotoxicity in l1210 cells: correlation with inhibition of thymidylate synthetase but not with incorporation into RNA. |
| Q44941786 | Study on the role of 5-fluorouracil in the polymerization of butylcyanoacrylate during the formation of nanoparticles. |
| Q33416158 | Survival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: a meta-analysis. |
| Q37901554 | Symptomatic 5-fluorouracil-induced sinus bradycardia |
| Q40264235 | Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer. |
| Q40038143 | Synthesis and bioevaluation of 5-fluorouracil derivatives. |
| Q52933943 | Synthesis and biological applications of fluoro-modified nucleic acids. |
| Q40050432 | Synthesis and biological evaluation of new 4beta-5-Fu-substituted 4'-demethylepipodophyllotoxin derivatives |
| Q39709630 | Synthesis and biological evaluation of new 5-fluorouracil-substituted ampelopsin derivatives. |
| Q39329841 | Synthesis of PEGylated fullerene-5-fluorouracil conjugates to enhance the antitumor effect of 5-fluorouracil |
| Q35111704 | Synthesis of novel spin-labeled derivatives of 5-FU as potential antineoplastic agents |
| Q42227659 | Synthesis of potential pyrimidine derivatives via Suzuki cross-coupling reaction as HIV and kinesin Eg5 inhibitors. |
| Q40258494 | Synthesis of virulence factors by Pasteurella pestis |
| Q37909031 | Synthesis, reactivity and biological activity of 5-alkoxymethyluracil analogues. |
| Q38796140 | Systemic Antifungal Agents: Current Status and Projected Future Developments. |
| Q44249171 | Systemic chemotherapy for metastatic colorectal cancer: reasons to combine |
| Q37109507 | Systemic therapy for metastatic colorectal cancer: current questions |
| Q36529843 | Systemic therapy strategies for head-neck carcinomas: Current status |
| Q38597310 | TAS-102, a novel antitumor agent: a review of the mechanism of action |
| Q38652269 | TAS-102: a novel antimetabolite for the 21st century |
| Q77156773 | THE EFFECT OF 5-IODO-2'-DESOXYURIDINE ON THE PROPAGATION OF SV 40 VIRUS IN TISSUE CULTURE |
| Q33994714 | THE MODE OF ACTION OF 5-FLUOROURACIL AND ITS DERIVATIVES |
| Q35973877 | Tailored chemotherapy for colorectal cancer: a new approach to therapy |
| Q92747984 | Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer |
| Q47646742 | Targeting Metabolism for Cancer Therapy. |
| Q35599748 | Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies |
| Q33815796 | The Mutator Phenotype in Cancer: Molecular Mechanisms and Targeting Strategies |
| Q39233316 | The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed. |
| Q37795648 | The Unique Potential for Noninvasive Imaging in Modernizing Drug Development and in Transforming Therapeutics: PET/MRI/MRS |
| Q78907567 | The biosynthesis of poliovirus in cell cultures |
| Q34054268 | The clinical impact of screening and other experimental tumor studies |
| Q34980526 | The dual role of thymidine phosphorylase in cancer development and chemotherapy |
| Q34761260 | The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil |
| Q39638939 | The effect of leucovorin on the therapeutic index of fluorouracil in cancer patients |
| Q42198572 | The effect of structural modifications of 5-fluorouracil derivatives on their transport and biodegradation by isolated rat jejunum |
| Q39927801 | The emergence of drug resistance in tumours: a characteristic which may be exploited therapeutically |
| Q52507634 | The essential role of folic acid and the effect of antimetabolites on growth and metamorphosis of housefly larvae Musca domestica L |
| Q51776805 | The high-affinity maltose switch MBP317-347 has low affinity for glucose: implications for targeting tumors with metabolically directed enzyme prodrug therapy. |
| Q52334121 | The mechanistic basis of pH-dependent 5-flucytosine resistance in Aspergillus fumigatus. |
| Q40003629 | The metabolism and pharmacology of 5-fluorouracil |
| Q72893958 | The metabolism of 5-fluorocytosine-214C and of cytosine-14C in the rat and the disposition of 5-fluorocytosine-214C in man |
| Q34211250 | The oral fluorinated pyrimidines |
| Q78983322 | The polymerization of 8-Azaguanosine 5′-diphosphate by polynucleotide phosphorylase |
| Q33352896 | The potentiation of radiation effects with 5-fluoro-uracil |
| Q53692873 | The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature. |
| Q35602147 | The role of funding and policies on innovation in cancer drug development |
| Q72720011 | The synthesis, characterization and biological properties of a new substance, 5-fluoropyrimidin-2-one |
| Q36038314 | The value of fluorinated pyrimidines in advanced malignancy |
| Q44929190 | Therapeutic evaluation of intralesional 5% 5-fluorouracil in condyloma acuminata |
| Q33884698 | Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer |
| Q24633384 | Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan |
| Q71832497 | Thermodynamic and Kinetic Aspects of the Reaction of γ-Fluoroglutamate with d-Glutamate Cyclase |
| Q34216779 | Thymidine analogues for tracking DNA synthesis. |
| Q39940923 | Thymidylate Synthetase |
| Q35183525 | Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment |
| Q81481891 | Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer |
| Q43932425 | Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy |
| Q40960400 | Thymidylate synthase in advanced gastrointestinal and breast cancers |
| Q37379373 | Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer |
| Q35549719 | Thymidylate synthetase - a target enzyme in cancer chemotherapy |
| Q40442939 | Topical and systemic antifungals in dermatology practice. |
| Q40307900 | Topical chemotherapy with 5-fluorouracil. A review |
| Q71299502 | Topical cytotoxic therapy of solar keratoses with 5-fluorouracil |
| Q70576748 | Topical therapy with 5‐fluorouracil |
| Q37207935 | Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy |
| Q80554169 | Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy |
| Q34438530 | Tramadol--a true natural product? |
| Q33233929 | Treatment of Genital Condylomata with Topical 5-Fluorouracil |
| Q33468659 | Treatment of cancer with weekly intravenous 5-fluorouracil.Study by the Western Cooperative Cancer Chemotherapy Group (WCCCG) |
| Q37255172 | Treatment of invasive candidiasis in immunocompromised pediatric patients |
| Q70580395 | Treatment of metastatic colorectal carcinoma with 5-fluorouracil by mouth |
| Q26774713 | Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer |
| Q71843761 | Tumor retention of 5-fluorouracil following irradiation observed using 19F nuclear magnetic resonance spectroscopy |
| Q35553869 | UFT and Oral Leucovorin as Radiation Sensitizers in Rectal and Other Gastrointestinal Malignancies |
| Q47129907 | Uncovering Large-Scale Conformational Change in Molecular Dynamics without Prior Knowledge |
| Q39789627 | Update in cancer chemotherapy: gastrointestinal cancer--colorectal cancer, Part 1. |
| Q79064008 | Use of 5-Fluorouracil in Disseminated Solid Neoplasms |
| Q35212953 | Use of capecitabine in management of early colon cancer |
| Q38997864 | Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: a shorter drug-free interval leads to more efficient antitumor effects. |
| Q42916637 | Variants in the Dihydropyrimidine Dehydrogenase, Methylenetetrahydrofolate Reductase and Thymidylate Synthase Genes Predict Early Toxicity of 5-Fluorouracil in Colorectal Cancer Patients |
| Q39406815 | What's new in treatment of pancreatic cancer: a patent review (2010-2017). |
| Q46906887 | Wnt9a Is Required for the Aortic Amplification of Nascent Hematopoietic Stem Cells |
| Q37425429 | XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center |
| Q78560478 | [Chemotherapy & bacterial resistance] |
| Q33532192 | [Human papillomavirus-associated warts in organ transplant recipients. Incidence, risk factors, management]. |
| Q33727842 | dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial |
| Q41767730 | dUTPase inhibition augments replication defects of 5-Fluorouracil. |
| Q33754032 | microRNA-200a-3p increases 5-fluorouracil resistance by regulating dual specificity phosphatase 6 expression |
Search more.